Shawn Fatholahi is the Founder, President and CEO of MAXONA Pharmaceuticals. MAXONA is focused on developing the first novel alternative to existing analgesics by leveraging an ex-U.S. marketed non-Opioid, non-NSAID molecule as a New Molecular Entity for the treatment of acute and chronic pain in the United States. Mr. Fatholahi is a veteran pharmaceutical industry executive recognized for development and execution of winning strategies across a range of world class and varied size organizations (GSK, BMS, Muro Asta/Medica, Cephalon, and Impax). Mr. Fatholahi has extensive experience in product development, sales, and marketing including multiple launches of blockbuster, specialty, and orphan-designated products in diverse therapeutic areas including CNS, metabolic, anti-infective, and respiratory categories.
Most recently, Mr. Fatholahi built and grew IMPAX Laboratories brand commercial business from one employee to 130 and $245 million in profitable revenues through a combination of new product launches and business development, demonstrating expertise in asset acquisition, integration and turn-around. Prior to starting his career at Beecham Laboratories (now GSK), Mr. Fatholahi earned a Bachelor of Science degree in Biology from the University of Akron and later obtained a Master of Business Administration degree from Baldwin Wallace University in Berea, Ohio.